S P E C T R E

Disclosure: This information is provided for informational purposes only and does not constitute investment advice. The individual solely bears the risk.

[S P E C T R E @Spectre_Trader]

@DonaldPond6 Free breakfasts and bigger child benefits sound generous, until you remember the bill lands on someone else's table.

[S P E C T R E @Spectre_Trader]

#POLB The upcoming EHA presentation is noise, not a catalyst. The real re-rating for @PoolbegPharma hinges on management proving they can bridge the gap between scientific data and a tangible licensing or development deal. It’s all about the conversion.

[Uni @AIMRANGER1]

@Spectre_Trader #POLB doing fantastic from lows , taking a breather now bit of consolidation here before the next move north

[S P E C T R E @Spectre_Trader]

#POLB Some weighty prints

[S P E C T R E @Spectre_Trader]

#POLB The weekly chart shows a significant recent breakout on strong volume. The price has successfully cleared the moving averages, which is a constructive technical development.

[S P E C T R E @Spectre_Trader]

#POLB With positive FDA feedback for POLB 001 and data presentations upcoming at EHA 2026, the technical momentum is finally catching up to the fundamental catalyst rich summer.

[Poolbeg Pharma @PoolbegPharma]

Tune in to hear from Chris Grimes-Crompton, Partner at Acumetis, who recently led market research highlighting #POLB 001s potential multi-billion-dollar peak sales opportunity.

Key takeaways from the conversation...

✅CRS remains a major barrier to wider uptake of CAR-T and bispecific therapies
✅US payers responded positively to POLB 001
✅Research showed payers were willing to reimburse POLB 001 at meaningful pricing levels
✅Feedback was highly consistent across both commercial insurers and government payers
✅The analysis highlighted that preventing CRS could not only improve patient safety and quality of life but also enable broader community-based administration of advanced cancer therapies in the future

Watch it here:
https://t.co/dMFH8fJ2kz

[S P E C T R E @Spectre_Trader]

@RUSSELL81748847 @MrChrisHutch The long teeth are actually one of the strongest indicators that this is a wild boar skull and not a badger skull.

[S P E C T R E @Spectre_Trader]

#POLB @AIMRANGER1 Where am ya? 😄

[S P E C T R E @Spectre_Trader]

#FUM The recent rally is a technical reaction to extreme capitulation, selling rather than an established upward trend. A real recovery requires volume expansion, higher lows, and stronger operational news flow.

[S P E C T R E @Spectre_Trader]

@TheMoneySponge #POLB EHA is taking place 11-14 June 2026 in Stockholm, Sweden. Catalyst rich summer. The share price could really start shifting gears.

[S P E C T R E @Spectre_Trader]

#POLB Cathal Friel must be grinning ear to ear. Poolbeg is looking spectacular.

[S P E C T R E @Spectre_Trader]

#NFX The price has struggled to break higher. A sustained close above the 200-day SMA is necessary for a technical breakout to occur.

[S P E C T R E @Spectre_Trader]

#NFX That BreakoutCV guy doesn't know his elbow from his arse. The current chart pattern does not provide a technical confirmation of an imminent breakout.

[faz_mustang @faz555]

@BreakoutCV #NFX please

[S P E C T R E @Spectre_Trader]

#POLB With positive FDA feedback for POLB 001 and data presentations upcoming at EHA 2026, the technical momentum is finally catching up to the fundamental catalyst rich summer.

[S P E C T R E @Spectre_Trader]

@AIMRANGER1
#POLB Very soon 🤞

[S P E C T R E @Spectre_Trader]

#NFX When is this supply going to be exhausted? 😄

[S P E C T R E @Spectre_Trader]

#NFX Management explicitly confirmed "on-going discussions with potential partners" for NXP002 in their fresh Interims. Any big buyer must be well aware of the timeline, swallowing multiple share blocks without letting the price escape 0.21p. A breakout here could be explosive.

[S P E C T R E @Spectre_Trader]

#POLB Great momentum for Poolbeg Pharma. Up over 60% YTD and building steady ground ahead of the anticipated H1/Summer catalysts. Strong setup with clear data readouts on the horizon.

[S P E C T R E @Spectre_Trader]

#POLB Two major human data readouts due in H1/Summer:

1️⃣ Oral GLP-1: Human PK data in the red-hot obesity space.

2️⃣ POLB 001: Interim data for cancer immunotherapy safety.
Fully funded, regulatory hurdles cleared, and data incoming.

The Cathal Friel Playbook.

[S P E C T R E @Spectre_Trader]

#NFX has been banging its head directly against resistance at 0.220p. Massive volume spike backing this test. The recent green volume bars dwarf anything seen in April or May. A daily close above this black line would completely shift the long-term trend.

[S P E C T R E @Spectre_Trader]

#NFX is a coiled spring, waiting for a potential out-licensing or partnership deal. If such an announcement is made, it's likely to re-rate.